Grifols | GRFS - Current Liabilities


Grifols reported EUR2.37B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 921K 153K Sep/2025
Arca Biopharma USD 15.37M 5.59M Dec/2025
aTyr Pharma USD 113.19M 97.51M Dec/2025
Bio Path USD 8.68M 819K Sep/2025
Brainstorm Cell Therapeutics USD 11.01M 1.98M Dec/2025
Capricor Therapeutics USD 35.84M 7.69M Dec/2025
Cara Therapeutics USD 11.04M 362K Sep/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024